

# OPTIMA HEALTH PLAN

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.

**Drug Requested:** Kalydeco® (ivacaftor)

**DRUG INFORMATION:** Complete below. If incomplete, authorization process will be delayed.

Drug Form/Strength/Quantity: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

Kalydeco® will **NOT** be covered for patients with FEV<sub>1</sub> ≥ 90 % initiation.

**CLINICAL CRITERIA:** Complete below. **ALL** lines **must** be completed to qualify. Include **all** labs. If incomplete, authorization will be delayed. Lab notes **MUST** be attached to this request.

- Patient is 2 years of age or older with a diagnosis of Cystic Fibrosis
- Patient is confirmed to have at least one of the following mutations in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene: **G551D, G1224E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H.. plus 28 more genes. (Laboratory documentation required.)**
  - Patient confirmed to have an R117H mutation in the CFTR gene. **(Laboratory documentation required.)**
  - Member is currently on at least two (2) of the following:
    - Dornase alfa
    - Hypertonic saline
    - Inhaled or oral antibiotics within the last 3 months continuous

**Initial Authorization Limit to 6 months. For Re-authorization member must show improvement from baseline of at least FEV1 7% and Sweat Chloride <60mmol/liter**

Baseline Date: \_\_\_\_\_ (within 3 months prior to Kalydeco) Re-Authorization Date: \_\_\_\_\_

FEV1: \_\_\_\_\_ FEV1: \_\_\_\_\_

Baseline Weight: \_\_\_\_\_

Sweat Chloride: \_\_\_\_\_ Sweat Chloride: \_\_\_\_\_

**Medication being provided by (check applicable box (es) below:**

**For Optima Commercial Members:**

**For Optima Family Care Members:**

PropriumRx

Sentara Norfolk General CM Pharmacy

**\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\***

**\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\***

Patient Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

\*Approved by Pharmacy and Therapeutics Committee: 5/17/2012

REVISED/UPDATED: 5/7/2014; 8/13/2014; 9/23/2014; 11/2/2014; 1/26/2015; 5/22/2015; 7/16/15; 11/12/15; 12/22/2015; 3/30/2016; 8/9/2016; 9/22/2016; 12/21/2016; 9/14/2017; 10/10/2017;